University of Illinois at Chicago
uic.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
509
Active
158
Phase 3
17
Total enrollment
360,268
Pipeline matrix
Showing 40 of 59 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Abemaciclib | — | — | — | — | — | 1 | |
| Flecainide | — | — | — | — | — | 1 | |
| Sotalol | — | — | — | — | — | 1 | |
| Amoxicillin + Clavulanate | — | — | — | — | — | 1 | |
| Ciprofloxacin + Metronidazole | — | — | — | — | — | 1 | |
| Granisetron Transdermal Patch | — | — | — | — | — | 1 | |
| Intravenous Dexamethasone | — | — | — | — | — | 1 | |
| Ondansetron | — | — | — | — | — | 1 | |
| Deferoxamine | — | — | — | — | — | 1 | |
| Elranatamab | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | 6 | ||
| Fludarabine | — | — | — | — | — | 4 | |
| Paclitaxel | — | — | — | — | 4 | ||
| Methotrexate | — | — | — | — | 3 | ||
| Busulfan | — | — | — | — | — | 3 | |
| Pembrolizumab | — | — | — | — | 2 | ||
| Sirolimus | — | — | — | — | — | 2 | |
| ATG | — | — | — | — | 3 | ||
| Docetaxel | — | — | — | — | 2 | ||
| Carboplatin | — | — | — | — | 2 | ||
| Pacliltaxel or Nab-paclitaxel | — | — | — | — | — | 1 | |
| Carboplatin or Cisplatin | — | — | — | — | — | 1 | |
| Cabozantinib | — | — | — | — | — | 1 | |
| Doxorubicin | — | — | — | — | — | 1 | |
| Alemtuzumab | — | — | — | — | — | 1 | |
| Conditioning regimen with half-matched (haploidentical) stem cell transplant | — | — | — | — | — | 1 | |
| Lactobacillus sakei proBio65 | — | — | — | — | — | 1 | |
| Melatonin | — | — | — | — | — | 1 | |
| Mesenchymal Stromal Cells | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Nab-paclitaxel | — | — | — | — | — | 1 | |
| Trastuzumab | — | — | — | — | — | 1 | |
| Pertuzumab | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Lenalidomide | — | — | — | — | — | 1 | |
| Clemastine Fumarate | — | — | — | — | — | 1 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Neoadjuvant chemotherapy | — | — | — | — | — | 1 | |
| Olanzapine | — | — | — | — | — | 1 | |
| mycophenolate mofetil | — | — | — | — | — | 1 |
19 more active programs hidden
Next readouts
- 2021-05-05
- 2026-02-02
- 2026-03-15
- 2026-04
- 2026-06-30
- 2026-07
- 2026-07
- 2026-09
- 2026-09-27
- 2026-09-28
Top conditions
- Obesity28
- Depression22
- Multiple Sclerosis13
- Stroke12
- Breast Cancer12
- Sickle Cell Disease11
- Anxiety10
- Prostate Cancer10
Frequently asked questions about University of Illinois at Chicago
- How many clinical trials does University of Illinois at Chicago have on ClinicalTrials.gov?
- University of Illinois at Chicago is listed as the lead sponsor on 509 clinical trials in ClinicalTrials.gov, 158 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Illinois at Chicago's trials are in Phase 3?
- 17 of University of Illinois at Chicago's trials are in Phase 3, spread across 59 active drug programs.
- What therapeutic areas does University of Illinois at Chicago focus on?
- University of Illinois at Chicago's most-studied conditions on ClinicalTrials.gov are Obesity, Depression, Multiple Sclerosis, Stroke, Breast Cancer.
- When are University of Illinois at Chicago's next clinical trial readouts?
- University of Illinois at Chicago has 10 upcoming primary-completion readouts tracked here; the soonest is “Convalescent Plasma as a Possible Treatment for COVID-19”, expected around 2021-05-05.